Trial Profile
Safety and efficacy study of romiplostim for the treatment of immune thrombocytopenia in patients who are resistant to prior therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2015
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Thrombocytopenia
- Focus Adverse reactions; Therapeutic Use
- 14 Dec 2015 New trial record